DJIA 16,643.01 -11.76 -0.07%
NASDAQ 4,828.33 15.62 0.32%
S&P 500 1,988.87 1.21 0.06%
market minute promo

Geron Corp (NASDAQ: GERN)

3.23 0.15 (4.87%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

GERN $3.23 4.87%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.09
Previous Close $3.08
Daily Range $3.05 - $3.23
52-Week Range $1.76 - $4.67
Market Cap $510.8M
P/E Ratio -12.83
Dividend (Yield) $0.00 (0.0%)
Volume 1,850,308
Average Daily Volume 2,170,571
Current FY EPS -$0.07




Drug Makers

Geron Corp (GERN) Description

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. Website:

News & Commentary

Could Geron Corporation Be the Next Big Biotech Winner?

Lets dig in to see if this small-cap stock could be the next home-run biotech investment.

SA Biotech Panel Discussion: Geron And Incyte, Imetelstat And Jakafi

Premarket Biotech Digest: Don't Panic Sell, Gilead Undervalued, Roche Acquiring GeneWEAVE

Geron Q2 Loss Narrower-than-Expected, Imetelstat in Focus - Analyst Blog

Morning Market Losers

Benzinga's Top #PreMarket Losers

3 Biotech Stocks That Could Double Before 2016

Here is a look at three small-cap biotech stocks with the potential to double within the next six months.

Geron's Second-Line Myelofibrosis Trial Offers Significant EPS Potential

Geron's Much Anticipated Imetelstat Phase 2 Study Grows To 50 Locations And Begins Enrollment

Orphan Drugs Series: Time From ODD To Market Approval

See More GERN News...

GERN's Top Competitors

GERN $3.23 (4.87%)
Current stock: GERN
AMGN $155.89 (0.11%)
Current stock: AMGN
GILD $107.78 (-0.19%)
Current stock: GILD
BIIB $303.69 (-0.26%)
Current stock: BIIB